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have distinct intracellular targets. A recent report 
(Goebl MG, Cell 1991; 64:1051-1052, Correspondence), 
tentatively identifying FKBP as a previously described 
12 kD endogenous inhibitor of protein kinase C, raises 
the possibility that FK 506 exerts its effect by blocking 
activation of protein kinase C, a key step in antigen- 
induced T-cell activation. One possible model inte- 
grating this report with the work of Bierer et al. would 
be that FK 506 must bind to FKBP to elicit the protein 
kinase C inhibitory capacity of FKBP. FK 506 might 
activate FKBP by a conformational change or by 
directing FKBP to the proper subcellular compartment. 
In either case, only the FK 506-FKBP complex is 
effective. Presumably, the rapamycin-FKBP complex 
acts in a different fashion or at a distinct intracellular 
site. 
These studies highlight how much has been learned in 
recent years of the molecular events initiated by T-cell 
activation. They also underscore the complexity of the 
immune response and the risks of predicting drug effects 
based solely on chemical similarities. Furthermore, the 
difficulty in determining whether drugs with apparently 
distinct effects in vitro will be useful in combination 
should serve to emphasize that there is no substitute for 
rigorous in  vivo testing. Ultimately, the goal of trans- 
plantation research is to induce a state of tolerance, or 
immunological unresponsiveness, to the graft. Although 
this remains an elusive goal, studies such as these 
advance us one step further by dissecting intracellular 
events that occur during the immune response. 
LAURENCE A. TURKA 
CRAIG B. THOMPSON 
Department of Internal Medicine 
Howard Hughes Medical Institute 
University of Michigan 











Hansen TH, Sachs, DH. The major histocompatibility complex. In: 
Paul WE, ed. Fundamental immunology. 2nd ed. New York: Raven 
Press Ltd, 1989:445-487. 
Halloran PF, Madrenas J. Regulation of MHC transcription. 
Transplantation 1990;50:725-738. 
Granelli-Piperno A. Lymphokine gene expression in uiuo is 
inhibited by cyclosporin A. J Exp Med 1990;171:533-544. 
Handschumacher RE, Harding MW, Rice J ,  Drugge RJ, Speicher 
DW. Cyclophilin: a specific cytosolic binding protein for cyclo- 
sporin A. Science 1984;226:544-547. 
Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. 
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably 
identical proteins. Nature 1989;337:476-478. 
Takahashi N, Hayano T, Suzuki M. Peptidyl-prolyl cis-tran 
isomerase is the cyclosporin A-binding protein cyclophilin. Nature 
Schreiber SL. Chemistry and biology of the immunophilins and 
their immunosuppressive ligands. Science 1991;251:283-287. 
Lagodzinski Z, Gorski A, Wasik M. Effect of FK506 and cyclo- 
sporine on primary and secondary skin allograft survival in mice. 
Immunology 1990;71: 148-150. 
Ochiai T, Sakamoto K, Gungi K, Hamaguchi K, Isegawa N, Suzuki 
T, Shimada H, et al. Effects of combination treatment with FK506 
1989;337:473-475. 
and cyclosporine on survival time and vascular changes in 
renal-allograft-recipient dogs. Transplantation 1989;48: 193- 
197. 
10. Dumont FJ, Melino MR, Staruchi MJ, Koprak SL, Fischer PA, 
Sigal NH. The immunosuppressive macrolides FK-506 and 
rapamycin act as reciprocal antagonists in murine T cells. 
J Immunol. 1990;144:1418-1424. 
11. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff 
SJ, Crabtree G, Schreiber SL. Two distinct signal transmission 
pathways in T lymphocytes are inhibited by complexes formed 
between an immunophilin and either FK506 or rapamycin. Proc 
Natl Acad Sci USA 1990;87:9231-9235. 
SPLIT-LIVER TRANSPLANTATION: ONE PLUS ONE 
DOESN’T ALWAYS EQUAL TWO 
Emond JC, Whitington PF, Thistlewaite JR ,  Cherqui D, 
Alonso EA, Woodle IS, Vogelbach P, et al. Transplan- 
tation of two patients with one liver: Analysis of a 
preliminary experience with “split-liver” grafting. Ann 
Surg 1990;212:14-22. 
ABSTRACT 
Surgical reduction of donor livers to treat small 
children has been performed successfully in several 
centers. While this procedure improves the allocation 
of livers, it does not increase the organ supply. We have 
extended reduced-size orthotopic liver transplan- 
tation (OLT) to treat 18 patients with 9 livers, ac- 
counting for 26% of our transplants during a 10-month 
period and have evaluated the results. In 18 split liver 
OLTs, patient survival was 67% and graft survival was 
50%. In comparison, for 34 patients treated with 
full-size OLT during the same period, patient survival 
was 84% (p = 0.298) and graft survival was 76% 
(p = 0.126). Biliary complications were significantly 
more frequent in split grafts, occurring in 27%, as 
compared to 4% in full-sized grafts (p = 0.017). Primary 
nonfunction (4% versus 5.5%) and arterial thrombosis 
(6% versus 9%) occurred with similar frequency in split 
and full-size OLT (p = not significant). These results 
demonstrated that split-liver OLT is feasible and could 
have a substantial impact in transplant practice. We 
believe that biliary complications can be prevented by 
technical improvements and that split-liver OLT will 
improve transplant therapy by making more livers 
available. 
Broelsch CE, Emond JC, Whitington PF, Thistlethwaite 
JR ,  Baker AL, Lichtor JL. Application of reduced-size 
liver transplants as split grafts, auxiliary orthotopic 
grafts, and living related segmental transplants. Ann 
Surg 1990;212:368-375. 
ABSTRACT 
The University of Chicago program in pediatric liver 
transplantation continues actively to seek innovative 
surgical solutions to problems related to the man- 
agement of children with end-stage liver disease. 
Among the most important problems facing these 
children is a shortage of donor organs, which results 
from three factors in addition to the actual supply of 
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pediatric donors: the concentration of pediatric liver 
disease in the population younger than 2 years; the 
necessity for a graft that is small enough; and the 
epidemiology of accidents and other events that lead to 
organ donation. Transplantation using a liver lobe as a 
graft overcomes size disparity and shifts the available 
supply of organs from older donors to younger recip- 
ients. This work describes the technical aspects of 
recent innovations in the use of liver lobes in pediatric 
transplantation, simple reduced-size liver transplan- 
tation (RLT), split-liver transplantation (SLT), ortho- 
topic auxiliary liver grafting (ALT), and transplan- 
tation using a living related donor (LRLT), and com- 
pares their results. Since November 1986 a total of 61 
procedures have been performed in which a liver lobe 
was used as a graft: 26 RLT; 30 SLT, 25 in children and 
5 in adults; 5 LRLT; and 1 ALT. Overall 62% of 
transplants performed in children have involved using 
a liver lobe as a graft. The rates of complications are 
somewhat higher than with whole-liver transplan- 
tation, but this may not be entirely the result of the 
complex procedures. Split liver transplantation is 
associated with the highest mortality and complication 
rates. Living related liver transplantation has been 
associated with complications in donors and recip- 
ients, but to date survival is 100%. Orthotopic a d l a r y  
liver transplantation effectively corrected the meta- 
bolic defect in one patient with ornithine transcarba- 
mylase deficiency. Overall the various modalities of 
using graft reduction have resulted in postoperative 
results similar to those achieved with full-size grafts, 
while pretransplantation mortality has been limited to 
less than 2%. Thus the use of grafts as liver lobes 
accomplishes the goal of reducing global mortality 
among children with end-stage liver disease, but at the 
cost of increased surgical complexity and more post- 
operative complications. 
COMMENTS 
From its clinical dawn in 1963 as a last ditch effort to 
save lives that were almost certainly past salvation, 
through 20 yr of pioneering surgical efforts primarily by 
Thomas Starzl in the United States and Roy Calne in 
England, orthotopic liver transplantation has reached 
the mainstream of hepatological therapy. As its appli- 
cation becomes ever wider, indications for transplan- 
tation appear to be limited only by the irreversibility of 
the underlying hepatic disorder and by the physiological 
reserve of the potential recipient. Recently, however, it 
has become clear that increasing numbers of otherwise 
treatable patients are dying from a shortage of donor 
organs. Children are at special risk because most 
cadaveric organ donors are adults, and in one report 25% 
of infant patients awaiting transplantation died for lack 
of a suitable organ ( 1). 
The number of liver transplant procedures performed 
in the United States increased each year from 1980 to 
1989, reflecting, in part, a growing acceptance of the 
procedure. However, the total number performed (more 
than 2,100 in 1989) also reflects an increasing per- 
centage of procurement of livers from an almost static 
number of cadaveric organ donors in this country (2).  
During the mid-l980s, the imbalance between the 
number of small children and infants awaiting liver 
grafting and the number of pediatric donors led to the 
development of successful techniques for transplan- 
tation of selected segments or lobes of an adult liver into 
a smaller, in some cases remarkably smaller, child or 
infant (3, 4). These innovative techniques use extant 
concepts of hepatic anatomy and surgical resection and 
have assumed a prominent place alongside whole organ 
grafting for children at many large centers, including 
our own. Reduced-size allograft patient survival rates of 
75% to 80% for infants have been reported and are 
comparable to results obtained with intact pediatric 
donor livers (5, 6). Using this approach, infant patient 
mortality for those on the waiting list has been reduced 
to 1%. to 2% (5). 
Unfortunately, two undesirable effects accompany 
the use of reduced-size liver allografts. First, with a 
nearly stable cadaveric organ donor pool this technique 
produces an allocation shift toward pediatric recipients 
because adult recipients who might otherwise have had 
transplants are bypassed. Second, given the increas- 
ingly desperate shortage of organs, the inevitable dis- 
carding of a large volume of otherwise well-preserved 
and viable hepatic parenchyma after the reduction is 
completed evokes in the transplant surgeon a sense of 
waste. 
It is these two issues that Emond and his colleagues 
from the University of Chicago have attempted to 
address in describing their results with the next step in 
the evolution of liver transplantation technique wherein 
two individuals are transplanted using one donor. Using 
two vascularized lobes or segments from a single donor, 
this surgical tour de force and the initial results in 18 
patients who had transplants from 9 donors testify to 
the authors’ technical slull and stamina. On closer 
examination, however, the suggestion that the “two for 
one” technique may, on wider application, solve the 
donor organ shortage appears to warrant a measure of 
skepticism. 
Given the technical complexity of the surgery and the 
poor condition of many recipients in the pediatric 
recipient population, a high incidence of complications is 
nearly assured. The difficulties encountered by Emond 
et al. were sufficient to lower graft survival after split 
liver transplantation to 50% from the 75% associated 
with whole organ and reduced-size allografts. This 
reduction in graft survival considerably dampens enthu- 
siasm for a technique intended to increase donor organ 
availability, especially when one considers that a whole 
organ or nonsplit reduced-size allograft will probably be 
used to replace a failed split liver graft. The high 
incidence of postoperative bleeding (33%) and biliary 
complications (27%) underscores the technical chal- 
lenges of this new procedure. Given the short follow-up 
period (2 to 12 mo), it is virtually certain that the actual 
1-yr patient survival rate will be lower than the crude 
67% figure cited by the authors. Despite these sobering 
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facts, it is likely that further experience with this 
technique will reduce the complication rate, and perhaps 
improved patient survival will result. 
The mathematics and geometry of reality dictated 
that 13 of the 18 recipients were children weighing 12 kg 
or less. This occurred because of the authors’ profoundly 
efficient use of five donors weighing less than 32 kg. At 
most centers, 30-kg donors are frequently used for a 
reduced-size graft for a single infant or not at all because 
the spectrum of liver disease results in few suitable 
recipients for a whole organ graft from a donor of this 
size. From this standpoint, the authors are to be 
commended for making the most of these donors. More 
careful examination of the data, however, reveals that 
three of the five adult recipients of a right lobe died, each 
of whom also received the medial segment of the left lobe 
(segment 4) in an attempt to provide an adequate volume 
of hepatic parenchyma. Whether routine removal of 
segment 4 from a liver providing a left lateral segment 
(segments 2 and 3) to a child and a right lobe (segments 
5 through 8) to an adult will result in more uniform 
success for recipients of both grafts remains speculative 
at this point. Thus a critical question regarding the 
ability of this technique to avoid the bypassing of 
size-appropriate adult recipients cannot be answered at 
this time. 
The second article from the University of Chicago 
team further illustrates the creativity and innovation of 
this group. In this report, Broelsch et al. describe the use 
of auxiliary orthotopic grafting and living-related seg- 
mental grafts in addition to the split liver technique. In 
what may be more appropriately called a partial ortho- 
topic liver transplant, the authors transplanted a left 
lateral segment graft into a 14-mo-old patient with 
ornithine transcarbamylase deficiency. The recipient’s 
own left lobe was resected, and the allograft segment was 
put in its place. This exciting approach to patients with 
metabolic defects whose livers are otherwise anatomi- 
cally and functionally normal is worthy of careful 
consideration if it can be demonstrated that the limited 
volume of transplanted hepatic parenchyma is capable of 
establishing and sustaining normal metabolism. Unfor- 
tunately, the number of patients who could be treated in 
this way are limited. 
Equally exciting and more controversial is the au- 
thors’ use of living relatives as liver donors for children 
with end-stage hepatic disease. The first five such 
patients are included in this report. All of the donors and 
recipients were alive at the time of publication, but 
serious complications occurred in several of the donors. 
One of the five recipients required retransplantation 
from a cadaveric donor. It is too early to pass judgment 
on the advisability (medical, ethical or otherwise) of this 
approach, and the authors have been careful to point out 
that the program is as yet entirely experimental. 
Further experience with the split liver technique was 
also included in the article by Broelsch et al. A total of 
30 transplants, including 5 in adults, were described. 
Many of these patients were presumably included in the 
article by Emond et al. Some of the issues previously 
raised appear closer to being answered by the data in the 
second article, in which four of the five adult recipients 
of split liver grafts died. The authors point out that they 
are now loathe to remove the left lobe from a liver 
intended to be transplanted into an adult and that livers 
from donors weighing less than 10 kg are unsuitable for 
splitting. This advice reinforces the concept that many 
donor livers too small for adults may still be successfully 
split into grafts for two pediatric recipients. It is 
important to point out, however, that donor organs of 
this size are not plentiful. Furthermore, having two 
disparately sized pediatric recipients available simulta- 
neously is required. 
The number of surgical teams may also limit wide- 
spread application of the split liver technique. Most 
transplant centers have developed teams who perform 
pancreas, kidney and liver transplants. These teams are 
highly specialized, and the members are few in number. 
Adopting the split liver approach requires mobilization 
of a multiorgan donor team to procure the organs and 
complete 3 to 4 hr of bench surgery, personnel to 
perform two liver transplants and potentially two or 
more additional teams to perform pancreatic and renal 
transplantation. If thoracic organ transplantation is 
added to the equation, the resource requirements at any 
given transplant center are considerable. Finally, the 
suggestion by the authors that the second recipient 
should be transplanted “at the priority of the left lobe 
recipient” may serve to undermine the admittedly 
imperfect attempts by the federally mandated United 
Network for Organ Sharing (UNOS) to ensure the fair 
and equitable distribution of organs. If the evolution of 
the split liver technique leads to success rates equivalent 
to whole organ or reduced size grafts, as the authors 
suggest it will, both lobes thus provided will have to be 
allocated separately under UNOS guidelines. 
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